On August 6, 2021, the U.S. Food and Drug Administration announced it has approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion for treatment of patients 1 year of age and older with late-onset Pompe disease. Individuals diagnosed of Pompe disease have an enzyme deficiency that causes the accumulation of a complex…

Amgen and Teneobio on July 27, 2021 announced they had reached an agreement which will see Amgen acquire Teneobio, a privately held, clinical stage biotechnology firm developing a new class of biologics known as Human Heavy-Chain Antibodies. Under the terms of the deal, Amgen will take over all outstanding shares…

The U.S. securities regulator in an exclusive report released on July 30 says it will not allow Chinese companies to undertake fundraising in the United States unless they wholly disclose their legal structures and explain the possibility of Beijing interfering in their businesses. In a related statement, Securities and Exchange…

Is there ample proof that Biogen’s new Alzheimer’s med Aduhelm is beneficial to patients, physicians and society beyond the existing routine care? The response from a team of ICER experts, maybe unsurprisingly, was “no.” During a daylong meeting Thursday involving debate over the drug’s costs and other issues, experts voted…

Is there ample proof that Biogen’s new Alzheimer’s med Aduhelm is beneficial to patients, physicians and society beyond the existing routine care? The response from a team of ICER experts, maybe unsurprisingly, was “no.” During a daylong meeting Thursday involving debate over the drug’s costs and other issues, experts voted…

Eli Lilly’s Covid-19 monoclonal antibody isn’t getting as much use as it could as a result of logistical issues. So the drugmaker is taking matters into its own hands. The company, in collaboration with local health systems, is opening dedicated local infusion centers across its home state of Indiana, with…

Billionaire investor Mark Cuban is renowned for critiquing startup plans on the hit TV series ‘Shark Tank,” often dismissing prospective entrepreneurs with the show’s famous line, “I’m out.” Cuban has also been a longtime critic of expensive health costs — and now he’s stepping in to offer a solution. Cuban…

Pharma companies globally scrambled to respond to the Covid-19 pandemic in early 2020, but so far only a handful have advanced therapies and vaccines through to the market. Regeneron is one of such companies, and now the Pharma giant’s antibody cocktail could bring a multibillion-dollar windfall in 2020. After previously…

Prevnar 13, Pfizer’s $5.8 billion-a-year vaccine is unarguably one of the firm’s top blockbusters and the undisputed leader in the pneumococcal vaccines’ market. But in terms of the next generation of pneumonia protection, Pfizer is facing a tough competitor in Merck. Merck is pulling close to Pfizer in the race…